389 related articles for article (PubMed ID: 28939451)
1. HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease.
Pawlowska AB; Cheng JC; Karras NA; Sun W; Wang LD; Bell AD; Gutierrez L; Rosenthal J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):185-189. PubMed ID: 28939451
[TBL] [Abstract][Full Text] [Related]
2. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
3. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
[TBL] [Abstract][Full Text] [Related]
4. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
[TBL] [Abstract][Full Text] [Related]
5. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors.
Anurathapan U; Hongeng S; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Charoenkwan P; Jetsrisuparb A; Sanpakit K; Rujkijyanont P; Meekaewkunchorn A; Lektrakul Y; Iamsirirak P; Surapolchai P; Satayasai W; Sirireung S; Sruamsiri R; Wahidiyat PA; Ungkanont A; Issaragrisil S; Andersson BS
Bone Marrow Transplant; 2016 Jun; 51(6):813-8. PubMed ID: 26878659
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.
Rangarajan HG; Abu-Arja R; Pai V; Guilcher GMT; Soni S
Biol Blood Marrow Transplant; 2018 Feb; 24(2):413-417. PubMed ID: 29061531
[TBL] [Abstract][Full Text] [Related]
8. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.
Bolaños-Meade J; Cooke KR; Gamper CJ; Ali SA; Ambinder RF; Borrello IM; Fuchs EJ; Gladstone DE; Gocke CB; Huff CA; Luznik L; Swinnen LJ; Symons HJ; Terezakis SA; Wagner-Johnston N; Jones RJ; Brodsky RA
Lancet Haematol; 2019 Apr; 6(4):e183-e193. PubMed ID: 30878319
[TBL] [Abstract][Full Text] [Related]
9. Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative.
de la Fuente J; Dhedin N; Koyama T; Bernaudin F; Kuentz M; Karnik L; Socié G; Culos KA; Brodsky RA; DeBaun MR; Kassim AA
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1197-1209. PubMed ID: 30500440
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
[TBL] [Abstract][Full Text] [Related]
11. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.
Horan JT; Liesveld JL; Fenton P; Blumberg N; Walters MC
Bone Marrow Transplant; 2005 Jan; 35(2):171-7. PubMed ID: 15531901
[TBL] [Abstract][Full Text] [Related]
13. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
Kharbanda S; Smith AR; Hutchinson SK; McKenna DH; Ball JB; Lamb LS; Agarwal R; Weinberg KI; Wagner JE
Biol Blood Marrow Transplant; 2014 Apr; 20(4):581-6. PubMed ID: 24370862
[TBL] [Abstract][Full Text] [Related]
14. Alternative Transplantation With Post-Transplantation Cyclophosphamide in Aplastic Anemia: A Retrospective Report From the BMF-WG of Hunan Province, China.
Gong S; Chen C; Chen K; Yang R; Wang L; Yang K; Hu J; Nie L; Su T; Xu Y; He X; Yang L; Xiao H; Fu B
Transplant Cell Ther; 2023 Jan; 29(1):48.e1-48.e7. PubMed ID: 36272527
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.
Peccatori J; Forcina A; Clerici D; Crocchiolo R; Vago L; Stanghellini MT; Noviello M; Messina C; Crotta A; Assanelli A; Marktel S; Olek S; Mastaglio S; Giglio F; Crucitti L; Lorusso A; Guggiari E; Lunghi F; Carrabba M; Tassara M; Battaglia M; Ferraro A; Carbone MR; Oliveira G; Roncarolo MG; Rossini S; Bernardi M; Corti C; Marcatti M; Patriarca F; Zecca M; Locatelli F; Bordignon C; Fleischhauer K; Bondanza A; Bonini C; Ciceri F
Leukemia; 2015 Feb; 29(2):396-405. PubMed ID: 24897508
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of fludarabine- and busulfan-based conditioning regimens in patients with acute myeloblastic leukemia: 8-year experience in a single center.
Kasar M; Asma S; Kozanoglu I; Maytalman E; Boga C; Ozdogu H; Yeral M
Transplant Proc; 2015 May; 47(4):1217-21. PubMed ID: 26036558
[TBL] [Abstract][Full Text] [Related]
17. Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non-Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Study in Japan.
Ikegame K; Yoshida T; Yoshihara S; Daimon T; Shimizu H; Maeda Y; Ueda Y; Kaida K; Ishii S; Taniguchi K; Okada M; Tamaki H; Okumura H; Kaya H; Kurokawa T; Kodera Y; Taniguchi S; Kanda Y; Ogawa H
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1495-505. PubMed ID: 25921715
[TBL] [Abstract][Full Text] [Related]
18. Augmented immunosuppression and PTCY-based haploidentical hematopoietic stem cell transplantation for thalassemia major.
Vellaichamy Swaminathan V; Ravichandran N; Ramanan KM; Meena SK; Varla H; Ramakrishnan B; Jayakumar I; Uppuluri R; Raj R
Pediatr Transplant; 2021 Mar; 25(2):e13893. PubMed ID: 33111490
[TBL] [Abstract][Full Text] [Related]
19. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
20. Successful Outcome in Patients with Fanconi Anemia Undergoing T Cell-Replete Mismatched Related Donor Hematopoietic Cell Transplantation Using Reduced-Dose Cyclophosphamide Post-Transplantation.
Ayas M; Siddiqui K; Al-Jefri A; Al-Ahmari A; Ghemlas I; Al-Saedi H; Alanazi A; Jafri R; Ayas MF; Al-Seraihi A
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2217-2221. PubMed ID: 31306778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
